STAT+: Eli Lilly’s much-anticipated obesity pill yields modest results
Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove disappointing.
Previous Post
Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy
Next Post
Government to limit high-risk cosmetic procedures to be carried out by doctors only
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago